PUBLIC COMPANY
saveViridian Therapeutics Inc
updated 15d ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 31pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillThree years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.fiercebiotech · 2d ago
- Viridian may have edge over Amgen in eye drug showdown, analysts argueThe FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.biopharma_dive · 1mo ago
- Ethyreal starts up with $101M and takes aim at a pair of immune diseasesThe startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.biopharma_dive · 2mo ago
- Viridian data lift prospects for thyroid eye disease drugWhereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.biopharma_dive · 3mo ago
- STAT+: Are analysts too quick to gloss over Lilly’s liver case?Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readoutstat · 3mo ago
comments(0)
5-min edit window · permanent after that